Denali Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DNLI research report →
Companywww.denalitherapeutics.com
Denali Therapeutics Inc. , a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.
- CEO
- Ryan J. Watts
- IPO
- 2017
- Employees
- 443
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $2.99B
- P/E
- -6.92
- P/S
- 0.00
- P/B
- 3.79
- EV/EBITDA
- -5.04
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -52.20%
- ROIC
- -46.93%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-512,540,000 · -21.23%
- EPS
- $-2.97 · -15.56%
- Op Income
- $-555,342,000
- FCF YoY
- -16.09%
Performance & Tape
- 52W High
- $23.77
- 52W Low
- $12.58
- 50D MA
- $19.83
- 200D MA
- $17.76
- Beta
- 0.99
- Avg Volume
- 1.74M
Get TickerSpark's AI analysis on DNLI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 10, 26 | Chin Peter Scott | other | 0 |
| Apr 10, 26 | Chin Peter Scott | other | 0 |
| Apr 10, 26 | Chin Peter Scott | other | 35,100 |
| Apr 10, 26 | Chin Peter Scott | other | 14,250 |
| Apr 10, 26 | Chin Peter Scott | other | 13,000 |
| Apr 10, 26 | Chin Peter Scott | other | 10,250 |
| Apr 10, 26 | Chin Peter Scott | other | 32,900 |
| Apr 10, 26 | Chin Peter Scott | other | 40,650 |
| Apr 10, 26 | Chin Peter Scott | other | 63,800 |
| Apr 10, 26 | Chin Peter Scott | other | 44,750 |
Our DNLI Coverage
We haven't published any research on DNLI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DNLI Report →